I am a
Home I AM A Search Login

Papers of the Week

Papers: 18 Nov 2023 - 24 Nov 2023

2023 Nov 22

J Headache Pain




Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registry.


Obach V, Velasco F, Alvarez Escudero R, Martín Bujanda M, Aranceta S, Fabregat N, Marco T, Ruisanchez A, Roncero N, Mínguez-Olaondo A, Ruibal M, Guisado-Alonso D, Moreira A, Cuadrado-Godia E, Echeverria A, Kortazar Zubizarreta I, López-Bravo A, Riesco N, González-Fernández L, Pola N, Manera P, Guerrero-Peral ÁL, Oterino Duran A, González-Osorio Y, Armand R, Fernández-Fernández S, García-Azorín D, García-Moncó JC


Galcanezumab has shown efficacy and effectiveness in the treatment of episodic and chronic migraine (CM), however, the population represented in randomized clinical trials (RCTs) differs from the population observed in real-world setting. To describe the long-term effectiveness and tolerability of galcanezumab in clinical practice in patients excluded from RCTs.